SCHEMBL135394

SCHEMBL135394

CC(C)c1cccc(Br)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MAPK1 P28482 1/20 0.48
IDO1 P14902 1/20 0.47
TDO2 P48775 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MDM4 O15151 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
TYR P14679 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
CA5A P35218 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427056 1.00 ALDH1A1 (0.48) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
Ammonia Solution, Strong SCHEMBL3178489 0.98 ALDH1A1 (0.46) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
Ammonia Solution, Strong SCHEMBL27726646 0.98 ALDH1A1 (0.46) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
SCHEMBL1223707 0.98 ALDH1A1 (0.46) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
Hydrochloric Acid SCHEMBL3176977 0.95 IDO1 (0.48) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
Methoxymethane SCHEMBL27727083 0.93 HDAC4 (0.48) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
SCHEMBL27794458 0.88 ALDH1A1 (0.43) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
SCHEMBL3171406 0.88 SMN1; SMN2 (0.40) ALDH1A1MAPK1IDO1TDO2SMN1; SMN2
SCHEMBL25914832 0.87 RXRA (0.51) ALDH1A1MAPK1SMN1; SMN2HDAC4HDAC8
SCHEMBL27661944 0.83 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2HDAC4HDAC8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109293568-B Method for synthesizing 3, 4-dihydroquinoline-3 ketone compound by using double-oxidation dehydrocyclization reaction 西北师范大学 2021-01-12 CN claimed
CN-102091657-B Method for preparing magnetic double-carbene palladium ligand catalyst and using method thereof INST PETROCHEMISTRY HEILONGJIANG ACADEMY OF SCIENCE 2013-02-06 CN claimed
CN-102091657-A Method for preparing magnetic double-carbene palladium ligand catalyst and using method thereof INST PETROCHEMISTRY HEILONGJIANG ACADEMY OF SCIENCE 2011-06-15 CN claimed
CN-117820191-B Diphenylamine compound and preparation method, application and pharmaceutical composition thereof FUDAN UNIVERSITY (CN) 2026-05-26 CN disclosed
CN-117659017-B TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2026-05-15 CN disclosed
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed
EP-4103557-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders JANSSEN PHARMACEUTICA NV (BE) 2025-12-23 US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 US disclosed
EP-4648762-A2 PPARG MODULATORS University of Florida Research Foundation, Incorporated (US) 2025-11-19 EP disclosed
EP-1362846-A1 AMINOETHANOL DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-11-19 EP disclosed
EP-1354603-A1 CONCOMITANT DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-10-22 EP disclosed
EP-1268474-A2 SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed
WO-2002096933-A1 2-{[N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL]-AMINO}-ALKYLBORONIC ACID DERIVATIVES NOVARTIS AG (CH) 2002-12-05 WO disclosed
US-6462248-B1 THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS TORAY INDUSTRIES, INC. (JP) 2002-10-08 US disclosed
EP-1205478-A1 p38MAP KINASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2002-05-15 EP disclosed
WO-2001074811-A2 SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-11 WO disclosed
EP-0985649-A2 Method for producing an aromatic compound having an alkyl group with at least three carbon atoms TORAY INDUSTRIES, INC. (JP) 2000-03-15 EP disclosed
CN-1065455-A Piperidine derivative LILLY CO ELI (US) 1992-10-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 ALDH1A1 2837/4885MAPK1 1308/4885IDO1 219/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 ALDH1A1 1006/4885MAPK1 983/4885IDO1 268/4885
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders LIPC, LPL, MGLL ALDH1A1 266/4885MAPK1 4715/4885IDO1 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.